Boston, MA 04/16/2014 (wallstreetpr) – Abbott Laboratories (NYSE:ABT) has recently hived off its research based proprietary pharmaceuticals business to give birth to a new company called AbbVie. In a bid to increase its expertise and diversity, ABT also acquired Optimedica Corporation and IDEV Technologies. The company has recently enrolled three clinical trials in a bid to support the approval of Absorb Bioresorbable Vascular Scaffold (BVS) in three countries namely Japan, the United States and China.
Business booster
With the U.S. Food and Drug Administration (FDA) granting clearance to a new test HbA1c which can quickly and accurately diagnose diabetes, the company is sure to gain further ground in the industry. This is especially significant in the context of thousands of people contracting diabetes every year. The count is growing significantly but more dangerous is the fact that lot of people are not even aware that they are suffering from diabetes.
FDA has also given approval to Supera® Peripheral Stent System which can cure patients with blockage in the arteries in the upper part of leg caused by peripheral artery disease (PAD). This disease affects nearly a fifth of the population in America, hitting people aged 65 or more and causes leg pain, besides rendering the patient more vulnerable to cardiac arrest.
Abbott Laboratories (NYSE:ABT)’s focus has been innovation which has propelled it to the league of Fortune 200 companies. With over 70,000 employees across the globe, the company is truly a global corporate citizen. The diversity of expertise, technology and geography provides that special edge which keeps the spirit of the company alive. A far reaching health care leader, ABT inspires trust and innovations that address health needs of mankind right from prevention to diagnosis to treatment. Abbott Laboratories (NYSE:ABT) has a tradition of catering successfully to all its stakeholders including patients and consumers, healthcare professionals, shareholders and its employees which truly makes it a cut above the rest.
